Vaccitech PLC VACC
We take great care to ensure that the data presented and summarized in this overview for Vaccitech plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VACC
View all-
M&G PLC London, X05.2MShares$17.7 Million0.02% of portfolio
-
M&G Investment Management LTD London, X05.2MShares$17.7 Million0.07% of portfolio
-
Alphabet Inc. Mountain View, CA1.51MShares$5.16 Million0.35% of portfolio
-
Sc China Holding LTD N/A, K31.42MShares$4.84 Million0.18% of portfolio
-
Dc Funds, LP Mclean, VA642KShares$2.19 Million33.3% of portfolio
-
Blue Crest Capital Management LTD St Helier, Y9543KShares$1.85 Million0.11% of portfolio
-
Johns Hopkins University Baltimore, MD122KShares$416,8280.01% of portfolio
-
Baird Financial Group, Inc. Milwaukee, WI92.5KShares$315,2920.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny27.9KShares$95,1390.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il27.7KShares$94,5140.0% of portfolio
Latest Institutional Activity in VACC
Top Purchases
Top Sells
About VACC
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Insider Transactions at VACC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 26
2023
|
Joseph Scheeren Director |
BUY
Open market or private purchase
|
Direct |
10,000
+30.3%
|
$20,000
$2.44 P/Share
|
|
May 25
2023
|
Robin Wright Director |
BUY
Open market or private purchase
|
Direct |
13,750
+22.18%
|
$27,500
$2.66 P/Share
|
|
Mar 27
2023
|
William Enright Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
15,000
-2.02%
|
$30,000
$2.42 P/Share
|
|
Sep 30
2022
|
M&G Investment Management LTD > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
4,108,752
+44.15%
|
-
|
|
Sep 30
2022
|
M&G Alternatives Investment Management LTD > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
4,108,752
-100.0%
|
-
|
|
Aug 25
2022
|
Graham Griffiths Chief Business Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.76%
|
$70,000
$7.39 P/Share
|
|
Aug 25
2022
|
Christopher Ellis Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
39,176
-67.91%
|
$235,056
$6.38 P/Share
|
|
Aug 25
2022
|
Christopher Ellis Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,176
+49.95%
|
-
|
|
Aug 24
2022
|
Christopher Ellis Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
450
-85.71%
|
$1,800
$4.78 P/Share
|
|
Aug 24
2022
|
Christopher Ellis Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
450
+46.15%
|
-
|
|
Aug 18
2022
|
Christopher Ellis Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,175
-96.67%
|
$8,700
$4.84 P/Share
|
|
Aug 18
2022
|
Christopher Ellis Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,175
+49.15%
|
-
|
|
Aug 17
2022
|
Graham Griffiths Chief Business Officer |
SELL
Open market or private sale
|
Direct |
500
-0.44%
|
$2,000
$4.76 P/Share
|
|
Aug 17
2022
|
Christopher Ellis Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
649
-89.64%
|
$2,596
$4.77 P/Share
|
|
Aug 17
2022
|
Christopher Ellis Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
649
+47.27%
|
-
|
|
Aug 16
2022
|
Graham Griffiths Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,220
-1.05%
|
$4,880
$4.82 P/Share
|
|
Aug 16
2022
|
Christopher Ellis Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,200
-96.7%
|
$8,800
$4.78 P/Share
|
|
Aug 16
2022
|
Christopher Ellis Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+49.16%
|
-
|
|
Aug 15
2022
|
Graham Griffiths Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,400
-2.03%
|
$9,600
$4.75 P/Share
|
|
Aug 15
2022
|
Christopher Ellis Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,350
-98.62%
|
$21,400
$4.76 P/Share
|